| Autor: |
Jian Wang, Yinghua Zou, Chao An, Xiaoqiang Tong, Tianai Mi, Tianshi Lyu |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.21203/rs.3.rs-208311/v1 |
| Popis: |
Background: There is a lack of evidence of standard or superior treatment among renal angiomyolipoma (RAML) patients. This study aimed to compare the short-term efficacy and safety using CalliSpheres microspheres (CSM) with conventional transcatheter arterial chemoembolization (cTACE) in treating Chinese patients with RAML. Methods: A total of 54 patients with RAML treated by TACE from February 2018 to April 2020 were retrospectively analyzed. These included 17 cases in the CSM-TACE group and 37 cases in the cTACE group. The clinical efficacy, tumor reduction rate and complications were compared between the two groups. Furthermore, blood routine indexes and kidney function test were compared between the two groups before and at the third day after the operation. Results: The embolization was performed successfully in all patients without serious adverse events and death. Except for abdominal pain (p=0.044) and white blood cell (WBC) (p=0.047), there were no significant differences in baseline characteristics (p>0.05). As for treatment efficacy, 42 patients with RAML had tumor size reduced after embolization. Compared with CSM-TACE group (0.12±0.34), tumor volume reduction rate was slightly higher in cTACE group (0.32±0.31) with p value 0.047. As for treatment safety, postoperative WBC and creatine level in two groups were both in normal range and not significantly different (p=0.114 and 0.659). Besides, no significant differences were observed in complication and length of stay after the operation between the two groups (p=0.347 and 0.593).Conclusions: CSM could be a safe and good option for embolization therapy in treating Chinese patients with RAML in clinical practices. Large cohort perspective study is still needed in the future. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
